Saltar al contenido
Merck

Management of epidermolysis bullosa acquisita.

Dermatologic clinics (2011-09-20)
Lizbeth R A Intong, Dédée F Murrell
RESUMEN

Epidermolysis bullosa acquisita is a rare and debilitating autoimmune mucocutaneous blistering disease caused by autoantibodies directed against type VII collagen or anchoring fibrils in the subepidermal basement membrane zone. Treatment is quite challenging because this disease can be recalcitrant to multiple modalities. This article discusses the current management of this disease.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Sulfapyridine, ≥99.0%
Supelco
Sulfapyridine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Sulfapyridine, VETRANAL®, analytical standard